Stefan Lethagen

Vice President Medical & Clinical Sciences
Sobi, Stockholm, Sweden

Presentation(s):

• OC 27.4 - Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A - results from A-SURE, a 24-month prospective, non-interventional study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM